组蛋白去乙酰化酶抑制剂药物及其专利信息分析  

Histone deacetylase inhibitors and related patent information

作　　者：钱丽娜 张长春 黄璐 

机构地区：[1]中美华世通生物医药科技(武汉)有限公司,武汉430075 [2]武汉国家生物产业创新基地有限公司,武汉430075 [3]人福医药集团股份公司,武汉430075

出　　处：《中国新药杂志》2016年第5期484-489,517,共7页Chinese Journal of New Drugs

基　　金：湖北省第一批知识产权示范建设企业建设工程(鄂知办〔2014〕55号)

摘　　要：组蛋白去乙酰化酶(HDAC)抑制剂作为新的靶向抗肿瘤药物,已成为当今肿瘤学研究的热点之一,为临床高效治疗肿瘤提供了更多选择。本文从HDAC抑制剂的代表性药物入手,对其相关专利申请状况进行分析和研究,并重点对其技术功效进行介绍,剖析该靶点药物布局中国专利的情况,为国内研发机构和企业进行新药研发以及专利布局策略提供有益的参考和建议。As new targeted anti-tumor drugs,histone deacetylase（ HDAC） inhibitors have become a hot topic in today＇s oncology research,and these drugs provide more choices for highly effective clinical treatment of tumors. Starting with the representative HDAC inhibitors,this article analyzed the related patent application situation,introduced its technical effect,and analyzed the patent layout of the target drugs in China. Lastly,some advice was put forwarded on new drug research and development and patent layout for domestic research and development institutions and enterprises.

关 键 词：组蛋白去乙酰化酶抑制剂 专利分析 仿制药 西达苯胺 

分 类 号：R95[医药卫生—药学]